- Data will highlight durability of treatment effect and significant impact on slowing disease progression. - No treatment-related serious adverse events (SAEs) or incidents of amyloid-related imaging ...

Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation ...

- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

Alzheimer's disease is a complicated and debilitating disease that has no cure. One startup is testing whether a "disco" of light and sound can slow the disease in patients. Cognito Therapeutics ...